Lifileucel, a heterogeneous TIL therapy, was given as a one-time infusion along with a median 5.5 infusions of IL-2 after a lymphodepleting regimen of cyclophosphamide and fludarabine to patients with stage III or IV melanoma who were unresponsive to both ICI therapy and targeted therapy [77]. Here, IL2 is linked to melanoma.